공시 • Apr 29
Motion for Case Conversion Filed by HTG Molecular Diagnostics, Inc. The Trustee filed a motion in the US Bankruptcy Court seeking the conversion of HTG Molecular Diagnostics, Inc.’s bankruptcy case from Chapter 11 reorganization to Chapter 7 liquidation on April 28, 2025. The reason for its conversion is sought due to no operations, no recovery prospects, and no feasible chapter 11 plan. 공시 • Jul 08
Nasdaq to Delist the Common Stock of HTG Molecular Diagnostics Nasdaq announced on July 06, 2023 that it will delist the common stock of HTG Molecular Diagnostics, Inc. The company’s securities were suspended on June 15, 2023, and have not traded on Nasdaq since that time. 공시 • Jun 16
HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index HTG Molecular Diagnostics, Inc. has been dropped from Nasdaq Composite Index. 공시 • Jun 08
HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index 공시 • Jun 07
Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer HTG Molecular Diagnostics, Inc. notified Byron T. Lawson, Senior Vice President and Chief Commercial Officer of the Company, of his termination of employment, effective June 2, 2023. In connection with his termination of employment, the Company has entered into a consulting agreement with Mr. Lawson pursuant to which Mr. Lawson has agreed to provide transition services to the Company for a period anticipated to be one month, in exchange for approximately $23,000. 공시 • Jun 06
HTG Molecular Diagnostics, Inc. Filed for Bankruptcy HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on June 5, 2023. The debtor listed both its assets and liabilities in the range of $1 million to $10 million. The debtor is represented by Zhao Liu and Frederick Brian Rosner of The Rosner Law Group LLC as its legal counsels. 공시 • May 25
HTG Molecular Diagnostics Receives Non-Compliance Notice From Nasdaq On May 18, 2023, HTG Molecular Diagnostics, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that, as a result of the Company’s stockholders’ equity falling below $2.5 million, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, the Company does not satisfy one of The Nasdaq Capital Market continued listing requirement set forth in Nasdaq Stock Market Rule 5550(b) (the “Rule”). Pursuant to the Notice and Nasdaq rules, the Company has 45 calendar days, or until July 3, 2023, to submit a plan to regain compliance with the Rule. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice for the Company to provide evidence of compliance. There can be no assurance that the Company will be able to regain compliance with the Rule. 공시 • May 19
HTG Molecular Diagnostics, Inc. to Highlight the Advantages of its Drug Discovery Engine at the 2023 Biotechnology Innovation Organization HTG Molecular Diagnostics, Inc. announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization (BIO) International Convention and will host in-person meetings during the remaining days of the June 5 - 8, 2023 event in Boston, MA. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treatment of diseases, with the ability to apply its platform agnostically across therapy areas. At the center of this approach is HTG's proprietary RNA profiling technologies, functionally married with an advanced medicinal chemistry using a novel artificial intelligence (AI)-driven platform, allowing for the improved selection and design of molecules. The company's most advanced discovery programs are in oncology with an emphasis on the treatment of acute myeloid leukemia (AML), with the first molecules currently progressing through the remaining portion of lead optimization and expected to have sufficient data to support entry into preclinical development in the third quarter of 2023. Reported Earnings • May 11
First quarter 2023 earnings: EPS and revenues miss analyst expectations First quarter 2023 results: US$2.28 loss per share (improved from US$9.73 loss in 1Q 2022). Revenue: US$1.03m (down 13% from 1Q 2022). Net loss: US$5.05m (loss narrowed 22% from 1Q 2022). Revenue missed analyst estimates by 35%. Earnings per share (EPS) also missed analyst estimates by 18%. Reported Earnings • Apr 02
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: US$24.28 loss per share. Revenue: US$6.37m (down 28% from FY 2021). Net loss: US$21.6m (loss widened 26% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 19%. Major Estimate Revision • Jan 11
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$5.69m to US$6.36m. EPS estimate unchanged at -US$21.08. Healthcare Services industry in the US expected to see average net income growth of 8.4% next year. Consensus price target of US$13.50 unchanged from last update. Share price fell 9.6% to US$3.58 over the past week. 공시 • Jan 10
HTG Molecular Diagnostics, Inc. Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event HTG Molecular Diagnostics, Inc. provided an update on the progress of its drug discovery business unit, including the filing of a patent application directed towards its first therapeutics target, and announced that its management team will be hosting in-person meetings at the LifeSci Partners 2023 Corporate Access Event from January 9-11, 2023 in San Francisco, CA. HTG Therapeutics, the company’s drug discovery business unit, has been actively using its transcriptome-informed approach to drug discovery to design and further refine small-molecule chemical libraries throughout 2022. This drug discovery platform is an integrated transcriptomic machine learning chemistry-based drug discovery engine that is expected to help overcome the traditional challenges of selecting and designing drug candidates by rendering a higher potential for success in development. The goal of this transcriptome-informed approach is to enable the selection and characterization of de-risked candidate molecules across selected therapeutic targets of interest leading to potential business development and licensing opportunities in various therapeutic areas. As a result of the progress made in 2022, the company filed a patent application on December 28, 2022, which included claims directed toward specific compounds, pharmaceutical compositions and methods of treating or preventing disease by administration of the compounds. HTG Therapeutics’ initial therapeutic pipeline is focused on oncology and degenerative neuroscience, emphasizing pharmacologic targets with understood roles in the progression of diseases in these areas. The most advanced discovery program in oncology is a small molecule program for treatment of liquid tumors. This program is expected to complete lead optimization at the end of the first quarter of 2023, with advancement to support entry into preclinical development later in the year. HTG has another oncology directed small molecule program for the treatment of a solid tumor type that is nearing completion in the hit-to-lead discovery phase, with lead optimization efforts planned through the second quarter of 2023 and subsequent preparation for potential preclinical development expected by the end of 2023. HTG expects to initiate several early discovery-stage programs evaluating small molecule candidates against a variety of different cancers, from which HTG plans to select candidates for additional indications as the company builds that portion of its overall drug discovery pipeline. In its neuroscience pipeline, the company has completed early discovery stage efforts and chemical library generation for candidate small molecules for application to neurodegenerative conditions which are expected to be in hit-to-lead by the second half of 2023. In parallel to these therapy-area specific programs, HTG continues to enrich the proprietary dataset supporting its transcriptome-informed drug discovery platform and continues to evolve and refine the complementary artificial intelligence and machine-learning portion of this novel engine throughout these discovery processes. 공시 • Jan 07
HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022 HTG Molecular Diagnostics, Inc. provided revenue guidance for full year 2022. For the period, total revenue is expected to be approximately $6.4 million, including approximately $2.7 million of HTG Transcriptome Panel (HTP) revenue representing 42% of total revenue. Major Estimate Revision • Nov 17
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$9.01m to US$5.69m. EPS estimate increased from -US$2.08 to -US$1.93 per share. Healthcare Services industry in the US expected to see average net income growth of 12% next year. Consensus price target of US$1.50 unchanged from last update. Share price rose 21% to US$0.58 over the past week. Reported Earnings • Nov 16
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2022 results: US$0.41 loss per share. Revenue: US$1.25m (down 50% from 3Q 2021). Net loss: US$4.52m (flat on 3Q 2021). Revenue missed analyst estimates by 56%. Earnings per share (EPS) exceeded analyst estimates by 23%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare Services industry in the US. Major Estimate Revision • Nov 12
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$9.01m to US$7.89m. EPS estimate increased from -US$2.08 to -US$2.04 per share. Healthcare Services industry in the US expected to see average net income growth of 12% next year. Consensus price target of US$2.25 unchanged from last update. Share price rose 2.1% to US$0.49 over the past week. Major Estimate Revision • Aug 19
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$10.8m to US$9.01m. EPS estimate increased from -US$2.33 to -US$2.08 per share. Healthcare Services industry in the US expected to see average net income growth of 19% next year. Consensus price target down from US$3.25 to US$2.25. Share price fell 18% to US$0.85 over the past week. Reported Earnings • Aug 12
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2022 results: US$0.54 loss per share (down from US$0.39 loss in 2Q 2021). Revenue: US$1.49m (down 28% from 2Q 2021). Net loss: US$5.89m (loss widened 125% from 2Q 2021). Revenue missed analyst estimates by 37%. Earnings per share (EPS) exceeded analyst estimates by 17%. Over the next year, revenue is forecast to grow 75%, compared to a 18% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. Price Target Changed • Jul 22
Price target decreased to US$3.25 Down from US$9.50, the current price target is an average from 2 analysts. New target price is 234% above last closing price of US$0.97. Stock is down 82% over the past year. The company is forecast to post a net loss per share of US$2.34 next year compared to a net loss per share of US$2.47 last year. Major Estimate Revision • May 19
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$12.8m to US$10.5m. EPS estimate increased from -US$2.40 to -US$2.18 per share. Healthcare Services industry in the US expected to see average net income growth of 19% next year. Consensus price target up from US$9.50 to US$15.00. Share price was steady at US$0.62 over the past week. Reported Earnings • May 13
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: US$0.81 loss per share (down from US$0.80 loss in 1Q 2021). Revenue: US$1.18m (down 18% from 1Q 2021). Net loss: US$6.50m (loss widened 34% from 1Q 2021). Revenue missed analyst estimates by 45%. Earnings per share (EPS) also missed analyst estimates by 13%. Over the next year, revenue is forecast to grow 103%, compared to a 17% growth forecast for the industry in the US. Price Target Changed • Apr 27
Price target decreased to US$9.50 Down from US$10.67, the current price target is an average from 2 analysts. New target price is 869% above last closing price of US$0.98. Stock is down 78% over the past year. The company is forecast to post a net loss per share of US$2.41 next year compared to a net loss per share of US$2.47 last year. Major Estimate Revision • Apr 05
Consensus revenue estimates fall by 16% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$15.3m to US$12.9m. Forecast losses increased from -US$2.10 to -US$2.24 per share. Healthcare Services industry in the US expected to see average net income growth of 21% next year. Consensus price target down from US$10.67 to US$7.33. Share price fell 11% to US$1.38 over the past week. Reported Earnings • Mar 30
Full year 2021 earnings: EPS exceeds analyst expectations Full year 2021 results: US$2.47 loss per share (up from US$4.51 loss in FY 2020). Revenue: US$8.91m (up 4.2% from FY 2020). Net loss: US$17.1m (loss narrowed 18% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.4%. Over the next year, revenue is forecast to grow 72%, compared to a 22% growth forecast for the industry in the US. Reported Earnings • Nov 12
Third quarter 2021 earnings released: US$0.60 loss per share (vs US$1.12 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$2.52m (up 42% from 3Q 2020). Net loss: US$4.49m (loss narrowed 17% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. Major Estimate Revision • Aug 19
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -US$2.70 to -US$2.27 per share. Revenue forecast steady at US$9.15m. Healthcare Services industry in the US expected to see average net income growth of 24% next year. Consensus price target of US$9.75 unchanged from last update. Share price rose 2.6% to US$6.25 over the past week. Reported Earnings • Aug 14
Second quarter 2021 earnings released: US$0.39 loss per share (vs US$1.30 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$2.07m (up 5.6% from 2Q 2020). Net loss: US$2.61m (loss narrowed 54% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. Reported Earnings • May 16
First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.27 loss in 1Q 2020) The company reported a soft first quarter result with weaker revenues and control over costs, although losses reduced. First quarter 2021 results: Revenue: US$1.44m (down 36% from 1Q 2020). Net loss: US$4.85m (loss narrowed 11% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings. Price Target Changed • May 16
Price target decreased to US$9.75 Down from US$11.50, the current price target is an average from 4 analysts. New target price is 174% above last closing price of US$3.56. Stock is down 44% over the past year. Reported Earnings • Mar 31
Full year 2020 earnings released: US$4.51 loss per share (vs US$7.60 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$8.55m (down 56% from FY 2019). Net loss: US$20.9m (loss widened 8.1% from FY 2019). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings. Major Estimate Revision • Mar 27
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$15.4m to US$11.1m. EPS estimate increased from -US$2.98 to -US$2.86 per share. Healthcare Services industry in the US expected to see average net income growth of 30% next year. Consensus price target down from US$13.84 to US$12.75. Share price fell 4.9% to US$5.65 over the past week. Price Target Changed • Mar 27
Price target decreased to US$11.75 Down from US$12.75, the current price target is an average from 4 analysts. New target price is 108% above last closing price of US$5.65. Stock is up 10% over the past year. Is New 90 Day High Low • Feb 17
New 90-day high: US$7.83 The company is up 84% from its price of US$4.25 on 18 November 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 32% over the same period. Is New 90 Day High Low • Jan 23
New 90-day high: US$7.27 The company is up 58% from its price of US$4.61 on 23 October 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 12% over the same period. Price Target Changed • Jan 06
Price target lowered to US$9.25 Down from US$12.75, the current price target is an average from 4 analysts. The new target price is 52% above the current share price of US$6.10. As of last close, the stock is down 46% over the past year. Is New 90 Day High Low • Jan 06
New 90-day high: US$6.10 The company is up 27% from its price of US$4.80 on 07 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Dec 10
New 90-day high: US$5.61 The company is up 16% from its price of US$4.84 on 10 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Major Estimate Revision • Dec 02
Analysts update estimates The company's losses in 2020 are expected to improve with analysts raising their consensus EPS forecasts from -US$4.90 to -US$3.39. No change was made to the revenue estimate which at the last update was US$8.03m. The Healthcare Services industry in the US is expected to see an average net income growth of 17% next year. The consensus price target was lowered from US$14.63 to US$12.75. Share price is up 8.6% to US$4.82 over the past week. Is New 90 Day High Low • Nov 13
New 90-day low: US$0.29 The company is down 36% from its price of US$0.46 on 14 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Reported Earnings • Nov 13
Third quarter 2020 earnings released: US$0.075 loss per share The company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$1.78m (down 67% from 3Q 2019). Net loss: US$5.41m (loss widened 14% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Analyst Estimate Surprise Post Earnings • Nov 13
Revenue and earnings miss expectations Revenue missed analyst estimates by 20%. Earnings per share (EPS) also missed analyst estimates by 16%. Over the next year, revenue is forecast to grow 25%, compared to a 40% growth forecast for the Healthcare Services industry in the US. Is New 90 Day High Low • Oct 23
New 90-day low: US$0.30 The company is down 54% from its price of US$0.65 on 24 July 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Sep 25
New 90-day low: US$0.30 The company is down 54% from its price of US$0.66 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.